A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
![OHE Report_Henderson et al](https://www.ohe.org/wp-content/uploads/2021/11/OHE-Report_Henderson-et-al._Multi-indication-Rare-Diseases-2-01.png)
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.